Brangre Vasseur - OSE Pharma Chief ImmunoOncology
| OSE Stock | EUR 6.22 0.05 0.80% |
Insider
Brangre Vasseur is Chief ImmunoOncology of OSE Pharma SA
| Phone | 33 2 28 29 10 10 |
| Web | https://www.ose-immuno.com |
OSE Pharma Management Efficiency
The company has return on total asset (ROA) of (0.0528) % which means that it has lost $0.0528 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1482) %, meaning that it generated substantial loss on money invested by shareholders. OSE Pharma's management efficiency ratios could be used to measure how well OSE Pharma manages its routine affairs as well as how well it operates its assets and liabilities.OSE Pharma SA has accumulated 34.77 M in total debt with debt to equity ratio (D/E) of 7.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. OSE Pharma SA has a current ratio of 2.49, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist OSE Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, OSE Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like OSE Pharma SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for OSE to invest in growth at high rates of return. When we think about OSE Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Noah MBA | Poxel SA | 61 | |
| Marc Bonneville | Innate Pharma | 63 | |
| Franck MBA | Valneva SE | 56 | |
| Kathryn McNeil | Nanobiotix SA | 48 | |
| Pascale MD | Poxel SA | N/A | |
| Joshua Drumm | Valneva SE | N/A | |
| Dipal Patel | Valneva SE | N/A | |
| Frederic Jacotot | Valneva SE | 58 | |
| Elizabeth MBA | Poxel SA | N/A | |
| Pr Prasad | Nanobiotix SA | 78 | |
| Sylvie Bertrand | Poxel SA | N/A | |
| DVM MBA | Innate Pharma | 58 | |
| Peter Buhler | Valneva SE | 52 | |
| Bart Rhijn | Nanobiotix SA | N/A | |
| Sophie HallakouBozec | Poxel SA | N/A | |
| Gerald Strohmaier | Valneva SE | N/A | |
| Alain Dostie | Nanobiotix SA | N/A | |
| Laurent Levy | Nanobiotix SA | 50 | |
| David MD | Poxel SA | N/A | |
| Bolze PharmD | Poxel SA | N/A | |
| Jean Fourni | Innate Pharma | N/A | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0528 |
OSE Pharma SA Leadership Team
Elected by the shareholders, the OSE Pharma's board of directors comprises two types of representatives: OSE Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OSE. The board's role is to monitor OSE Pharma's management team and ensure that shareholders' interests are well served. OSE Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OSE Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brangre Vasseur, Chief ImmunoOncology | ||
| Alain MD, Medical Director | ||
| Silvia MD, Head Devel | ||
| Nicolas Poirier, Scientific Director | ||
| AnneLaure AutretCornet, Chief Financial and Administrative Officer | ||
| JeanPascal PharmD, Chief Person | ||
| Dominique MD, Chairman Founder | ||
| Alexis Peyroles, Consultant | ||
| Julien Perrier, Chief Commercial Officer | ||
| Linda MSc, Chief Officer |
OSE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OSE Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0528 | |||
| Profit Margin | (0.22) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 128.18 M | |||
| Shares Outstanding | 18.44 M | |||
| Shares Owned By Insiders | 39.03 % | |||
| Shares Owned By Institutions | 1.81 % | |||
| Price To Earning | 10.60 X | |||
| Price To Book | 2.64 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in OSE Stock
OSE Pharma financial ratios help investors to determine whether OSE Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in OSE with respect to the benefits of owning OSE Pharma security.